Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003179 · ClinicalTrials.gov registry record · Phase 2
Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT00003179 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 360 participants.
The verdict
NCT00003179, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development of endometrial cancer in patients who have endometrial hyperplasia. PURPOSE: Phase II trial to compare the effectiveness of surgery alone with that of medroxyprogesterone followed by surgery in preventing endometrial cancer in patients who have endometrial hyperplasia.
Interventions
- DRUG medroxyprogesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 1998-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003179
The ClinicalTrials.gov registry entry for NCT00003179 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which medroxyprogesterone is the first listed.
NCT00003179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003179 about?
NCT00003179 is a clinical study titled "Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development of endometrial cancer in patients who have endometrial hyperplasia. PUR...
What is the current status of trial NCT00003179?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 1998-11.
What interventions are being tested in trial NCT00003179?
The interventions under investigation include: medroxyprogesterone (DRUG).
Who is sponsoring clinical trial NCT00003179?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.